Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q8N6T7: Variant p.Asp116Asn

NAD-dependent protein deacylase sirtuin-6
Gene: SIRT6
Feedback?
Variant information Variant position: help 116 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LB/B The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Aspartate (D) to Asparagine (N) at position 116 (D116N, p.Asp116Asn). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and acidic (D) to medium size and polar (N) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Polymorphism: help Variability among SIRT6 alleles may account for variations in life span (PubMed:25541994). A minor allele (rs107251) is associated with a decreased life span of 5.5 and 5.9 years when homozygous (TT); when compared to the major allele homozygous (CC) and heterozygous (CT) genotypes, respectively (PubMed:25541994). Additional information on the polymorphism described.
Variant description: help Found in non-small cell lung cancer; somatic mutation; reduced localization to chromatin; strongly reduced histone deacetylase activity; strongly reduced the protein-lysine demyristoylase activity. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 116 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 355 The length of the canonical sequence.
Location on the sequence: help MALVQLERVGLLRFLVSQNV D GLHVRSGFPRDKLAELHGNM The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         MALVQLERVGLLRFLVSQNVDGLHVRSGFPRDKLAELHGNM

Mouse                         MALVQLERMGFLSFLVSQNVDGLHVRSGFPRDKLAELHGNM

Drosophila                    MAIIALIESGYVQYVISQNIDGLHLKSGLDRKYLSELHGNI

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 2 – 355 NAD-dependent protein deacylase sirtuin-6
Domain 27 – 272 Deacetylase sirtuin-type
Active site 133 – 133 Proton acceptor
Binding site 113 – 113
Binding site 133 – 133
Mutagenesis 133 – 133 H -> Y. Abolished NAD-dependent protein deacetylase, deacylase and mono-ADP-ribosyltransferase activities. Impaired ability to recognize and bind double-strand breaks (DSBs) sites.



Literature citations
Identification of and molecular basis for SIRT6 loss-of-function point mutations in cancer.
Kugel S.; Feldman J.L.; Klein M.A.; Silberman D.M.; Sebastian C.; Mermel C.; Dobersch S.; Clark A.R.; Getz G.; Denu J.M.; Mostoslavsky R.;
Cell Rep. 13:479-488(2015)
Cited for: VARIANTS ASN-25; VAL-36; ASN-46; TYR-63; SER-89; ASN-116; 260-GLU--SER-355 DEL; PRO-263 AND LEU-274; FUNCTION; CATALYTIC ACTIVITY; SUBCELLULAR LOCATION; CHARACTERIZATION OF VARIANTS ASN-25; VAL-36; ASN-46; TYR-63; SER-89; ASN-116; 260-GLU--SER-355 DEL; PRO-263 AND LEU-274;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.